RxDoctor Payments Data

Sonia Deora, DO

Family Medicine · Princeton, NJNPI 1235134297

Payments from drug & device makers

$10,328in general payments, 2019–2025

Across 651 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • AbbVie$968
  • Boehringer Ingelheim$802
  • Bayer$467
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$10,320100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,328 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$61,544
Medicare patients
168
Services billed
578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$77,664
JardianceEmpagliflozin30$40,454
EliquisApixaban29$32,164
JanuviaSitagliptin Phosphate27$31,150
FarxigaDapagliflozin Propanediol18$24,588
MounjaroTirzepatide16$24,581
Repatha SureclickEvolocumab12$6,086
LexaproEscitalopram Oxalate14$5,987
VascepaIcosapent Ethyl15$4,547
Qvar RedihalerBeclomethasone Dipropionate12$3,460
Celecoxib33$3,352
Rosuvastatin Calcium225$3,189
Atorvastatin Calcium266$2,399
Levothyroxine Sodium236$2,042
Omeprazole91$1,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,032$77,66456 claims
Boehringer IngelheimJardiance$802$40,45430 claims
PfizerEliquis$151$32,16429 claims
MerckJanuvia$328$31,15027 claims
AstraZenecaFarxiga$3,204$24,58818 claims
Lilly USA, LLCMounjaro$1,048$24,58116 claims
AbbVieLexapro, Synthroid$968$7,88453 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$43$3,46012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Princeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →